Raj Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raj Kumar has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Bal Ram Singh
Institute of Advanced Sciences
5 shared publications- Bal Ram Singh
Botulinum Research Center, Institute of Advanced Sciences, Dartmouth, MA 02747, USA
5 shared publications - Shuowei Cai
University of Massachusetts Dartmouth
2 shared publications Aisha Furey
Botulinum Research Center (BRC), The Institute of Advanced Sciences (INADS)
1 shared publicationHarkiran Preet Kaur Dhaliwal
Institute of Advanced Sciences
1 shared publication- Kruti B. Patel
Botulinum Research Center, Institute of Advanced Sciences, Dartmouth, MA 02747, USA
1 shared publication
Latest Publications
- Open Access
- 25 June 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 13, 1855747
BoNT/E-associated protein disrupts intestinal epithelial barrier integrity to facilitate transcytosis
Background: Epithelial and endothelial barriers play essential roles in maintaining compartmentalization within the body through specialized intercellular junctional complexes. Botulinum neurotoxin type E (BoNT/E), a ~150 kDa protein toxin produced by Clostridium botulinum , is capable of traversing the intestinal epithelial barrier despite its large molecular size. BoNT/E is produced in association with several neurotoxin-associated proteins (NAPs), which are believed to facilitate toxin stability and absorption. Among these, an approximately 80 kDa protein (P80), corresponding to OrfX2, has been identified as a BoNT/E-associated protein; however, its functional role in epithelial transport remains poorly understood. Methods: P80 was purified from the BoNT/E progenitor toxin complex and characterized using circular dichroism spectroscopy and thermal denaturation analysis. Its biological activity was evaluated using hemagglutination assays, cytotoxicity studies, confocal microscopy, atomic force microscopy (AFM), immunofluorescence imaging, tight junction protein analysis, and transcytosis assays in Caco-2 and HT-29 intestinal epithelial cell models. Results: Structural analyses revealed that P80 is a stable, predominantly α-helical protein with a well-defined tertiary structure. P80 exhibited no detectable hemagglutination activity and showed minimal cytotoxicity toward intestinal epithelial cells. Cellular studies demonstrated that P80 interacts with epithelial monolayers, induces actin cytoskeletal remodeling, increases claudin-1 phosphorylation, and alters tight junction organization. AFM and confocal microscopy revealed changes consistent with transient modulation of epithelial barrier integrity. Functional transcytosis studies showed that P80 significantly enhanced the transport of co-incubated macromolecular cargo across polarized Caco-2 monolayers, resulting in approximately a fivefold increase in translocation compared with untreated controls. Discussion: These findings demonstrate that P80 functions as a non-toxic modulator of epithelial barrier permeability capable of enhancing paracellular transport of large biomolecules. Unlike classical hemagglutinin-associated neurotoxin proteins, P80 lacks hemagglutination activity while retaining the ability to reversibly alter tight junction dynamics. The results suggest that P80 contributes to BoNT/E intestinal absorption and may serve as a promising bioenhancer for improving mucosal delivery of therapeutic proteins and other hydrophilic macromolecules. Further mechanistic and in vivo studies are warranted to evaluate its translational potential.
- 25 June 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 13, 1855747
Open AccessBoNT/E-associated protein disrupts intestinal epithelial barrier integrity to facilitate transcytosis
Background: Epithelial and endothelial barriers play essential roles in maintaining compartmentalization within the body through specialized intercellular junctional complexes. Botulinum neurotoxin type E (BoNT/E), a ~150 kDa protein toxin produced by Clostridium botulinum , is capable of traversing the intestinal epithelial barrier despite its large molecular size. BoNT/E is produced in association with several neurotoxin-associated proteins (NAPs), which are believed to facilitate toxin stability and absorption. Among these, an approximately 80 kDa protein (P80), corresponding to OrfX2, has been identified as a BoNT/E-associated protein; however, its functional role in epithelial transport remains poorly understood. Methods: P80 was purified from the BoNT/E progenitor toxin complex and characterized using circular dichroism spectroscopy and thermal denaturation analysis. Its biological activity was evaluated using hemagglutination assays, cytotoxicity studies, confocal microscopy, atomic force microscopy (AFM), immunofluorescence imaging, tight junction protein analysis, and transcytosis assays in Caco-2 and HT-29 intestinal epithelial cell models. Results: Structural analyses revealed that P80 is a stable, predominantly α-helical protein with a well-defined tertiary structure. P80 exhibited no detectable hemagglutination activity and showed minimal cytotoxicity toward intestinal epithelial cells. Cellular studies demonstrated that P80 interacts with epithelial monolayers, induces actin cytoskeletal remodeling, increases claudin-1 phosphorylation, and alters tight junction organization. AFM and confocal microscopy revealed changes consistent with transient modulation of epithelial barrier integrity. Functional transcytosis studies showed that P80 significantly enhanced the transport of co-incubated macromolecular cargo across polarized Caco-2 monolayers, resulting in approximately a fivefold increase in translocation compared with untreated controls. Discussion: These findings demonstrate that P80 functions as a non-toxic modulator of epithelial barrier permeability capable of enhancing paracellular transport of large biomolecules. Unlike classical hemagglutinin-associated neurotoxin proteins, P80 lacks hemagglutination activity while retaining the ability to reversibly alter tight junction dynamics. The results suggest that P80 contributes to BoNT/E intestinal absorption and may serve as a promising bioenhancer for improving mucosal delivery of therapeutic proteins and other hydrophilic macromolecules. Further mechanistic and in vivo studies are warranted to evaluate its translational potential.
- Open Access
- 22 January 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (2) , 146
Transdermal Delivery of Botulinum Neurotoxin A: A Novel Formulation with Therapeutic Potential
Background: Botulinum neurotoxin is widely regarded as a “wonder medicine” due to its therapeutic efficacy in treating a variety of conditions. While it is traditionally classified as a neurotoxin, it is arguably more appropriate to refer to it as a neuromedicine. All FDA-approved formulations of botulinum neurotoxin are currently administered through intramuscular injections, with no other delivery methods widely used. The primary reasons for this include the following: (a) the extremely high potency of the toxin, (b) the potential for diffusion to adjacent muscles, (c) factors related to the site of administration (e.g., muscle thickness), (d) the large size of the molecule, (e) the impermeability of skin to large protein molecules, and (f) safety concerns. Despite these challenges, there is growing interest in the development of an effective transdermal formulation of botulinum neurotoxin. Refining and standardizing the delivery technology for topical or transdermal use remains an important goal for the future. Methods: The aim of this study was to develop a nanoemulsion-based transdermal formulation capable of delivering active botulinum neurotoxin (BoNT) through human skin. The goal was to demonstrate its efficacy in a mouse model, highlighting the therapeutic effects on both neuromuscular activity and hyperhidrosis. We successfully developed a nanoemulsion-based formulation that facilitates the transdermal delivery of BoNT. The formulation was homogeneous, stable, and efficacious. In a mouse model, we evaluated the neurotoxin’s impact on neuromuscular function using the Digital Abduction Score (DAS) for toe-spread and rota-rod assay to assess motor coordination. Results: The results confirmed the successful paralytic effect of the neuotoxin. The formulation significantly reduced sweating in the hyperhidrosis mouse model, indicating the therapeutic potential for this indication. Beyond the neurotoxin’s paralyzing effect, we also observed the recovery of nerve function, showing that the neurotoxin does not cause permanent damage, further underscoring its safety and efficacy. Conclusions: This formulation is the first of its kind to successfully deliver a large biomolecule like BoNT across the skin and produce a therapeutic effect. The ability to deliver large biomolecules transdermally has the potential to serve as a platform technology for treating a variety of conditions, including neuromuscular disorders, skin conditions, and localized pain management.
- 22 January 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (2) , 146
Open AccessTransdermal Delivery of Botulinum Neurotoxin A: A Novel Formulation with Therapeutic Potential
Background: Botulinum neurotoxin is widely regarded as a “wonder medicine” due to its therapeutic efficacy in treating a variety of conditions. While it is traditionally classified as a neurotoxin, it is arguably more appropriate to refer to it as a neuromedicine. All FDA-approved formulations of botulinum neurotoxin are currently administered through intramuscular injections, with no other delivery methods widely used. The primary reasons for this include the following: (a) the extremely high potency of the toxin, (b) the potential for diffusion to adjacent muscles, (c) factors related to the site of administration (e.g., muscle thickness), (d) the large size of the molecule, (e) the impermeability of skin to large protein molecules, and (f) safety concerns. Despite these challenges, there is growing interest in the development of an effective transdermal formulation of botulinum neurotoxin. Refining and standardizing the delivery technology for topical or transdermal use remains an important goal for the future. Methods: The aim of this study was to develop a nanoemulsion-based transdermal formulation capable of delivering active botulinum neurotoxin (BoNT) through human skin. The goal was to demonstrate its efficacy in a mouse model, highlighting the therapeutic effects on both neuromuscular activity and hyperhidrosis. We successfully developed a nanoemulsion-based formulation that facilitates the transdermal delivery of BoNT. The formulation was homogeneous, stable, and efficacious. In a mouse model, we evaluated the neurotoxin’s impact on neuromuscular function using the Digital Abduction Score (DAS) for toe-spread and rota-rod assay to assess motor coordination. Results: The results confirmed the successful paralytic effect of the neuotoxin. The formulation significantly reduced sweating in the hyperhidrosis mouse model, indicating the therapeutic potential for this indication. Beyond the neurotoxin’s paralyzing effect, we also observed the recovery of nerve function, showing that the neurotoxin does not cause permanent damage, further underscoring its safety and efficacy. Conclusions: This formulation is the first of its kind to successfully deliver a large biomolecule like BoNT across the skin and produce a therapeutic effect. The ability to deliver large biomolecules transdermally has the potential to serve as a platform technology for treating a variety of conditions, including neuromuscular disorders, skin conditions, and localized pain management.
- Top Cited PapersOpen Access
- 17 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (2) , 777
Botulinum Toxin: A Comprehensive Review of Its Molecular Architecture and Mechanistic Action
Botulinum toxin (BoNT), the most potent substance known to humans, likely evolved not to kill but to serve other biological purposes. While its use in cosmetic applications is well known, its medical utility has become increasingly significant due to the intricacies of its structure and function. The toxin’s structural complexity enables it to target specific cellular processes with remarkable precision, making it an invaluable tool in both basic and applied biomedical research. BoNT’s potency stems from its unique structural features, which include domains responsible for receptor recognition, membrane binding, internalization, and enzymatic cleavage. This division of labor within the toxin’s structure allows it to specifically recognize and interact with synaptic proteins, leading to precise cleavage at targeted sites within neurons. The toxin’s mechanism of action involves a multi-step process: recognition, binding, and catalysis, ultimately blocking neurotransmitter release by cleaving proteins like SNAP-25, VAMP, and syntaxin. This disruption in synaptic vesicle fusion causes paralysis, typically in peripheral neurons. However, emerging evidence suggests that BoNT also affects the central nervous system (CNS), influencing presynaptic functions and distant neuronal systems. The evolutionary history of BoNT reveals that its neurotoxic properties likely provided a selective advantage in certain ecological contexts. Interestingly, the very features that make BoNT a potent toxin also enable its therapeutic applications, offering precision in treating neurological disorders like dystonia, spasticity, and chronic pain. In this review, we highlight the toxin’s structural, functional, and evolutionary aspects, explore its clinical uses, and identify key research gaps, such as BoNT’s central effects and its long-term cellular impact. A clear understanding of these aspects could facilitate the representation of BoNT as a unique scientific paradigm for studying neuronal processes and developing targeted therapeutic strategies.
- 17 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (2) , 777
Top Cited PapersOpen AccessBotulinum Toxin: A Comprehensive Review of Its Molecular Architecture and Mechanistic Action
Botulinum toxin (BoNT), the most potent substance known to humans, likely evolved not to kill but to serve other biological purposes. While its use in cosmetic applications is well known, its medical utility has become increasingly significant due to the intricacies of its structure and function. The toxin’s structural complexity enables it to target specific cellular processes with remarkable precision, making it an invaluable tool in both basic and applied biomedical research. BoNT’s potency stems from its unique structural features, which include domains responsible for receptor recognition, membrane binding, internalization, and enzymatic cleavage. This division of labor within the toxin’s structure allows it to specifically recognize and interact with synaptic proteins, leading to precise cleavage at targeted sites within neurons. The toxin’s mechanism of action involves a multi-step process: recognition, binding, and catalysis, ultimately blocking neurotransmitter release by cleaving proteins like SNAP-25, VAMP, and syntaxin. This disruption in synaptic vesicle fusion causes paralysis, typically in peripheral neurons. However, emerging evidence suggests that BoNT also affects the central nervous system (CNS), influencing presynaptic functions and distant neuronal systems. The evolutionary history of BoNT reveals that its neurotoxic properties likely provided a selective advantage in certain ecological contexts. Interestingly, the very features that make BoNT a potent toxin also enable its therapeutic applications, offering precision in treating neurological disorders like dystonia, spasticity, and chronic pain. In this review, we highlight the toxin’s structural, functional, and evolutionary aspects, explore its clinical uses, and identify key research gaps, such as BoNT’s central effects and its long-term cellular impact. A clear understanding of these aspects could facilitate the representation of BoNT as a unique scientific paradigm for studying neuronal processes and developing targeted therapeutic strategies.
- Open Access
- 23 October 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (11) , 2206
Clostridial Neurotoxins: Structure, Function and Implications to Other Bacterial Toxins
Gram-positive bacteria are ancient organisms. Many bacteria, including Gram-positive bacteria, produce toxins to manipulate the host, leading to various diseases. While the targets of Gram-positive bacterial toxins are diverse, many of those toxins use a similar mechanism to invade host cells and exert their functions. Clostridial neurotoxins produced by Clostridial tetani and Clostridial botulinum provide a classical example to illustrate the structure–function relationship of bacterial toxins. Here, we critically review the recent progress of the structure–function relationship of clostridial neurotoxins, including the diversity of the clostridial neurotoxins, the mode of actions, and the flexible structures required for the activation of toxins. The mechanism clostridial neurotoxins use for triggering their activity is shared with many other Gram-positive bacterial toxins, especially molten globule-type structures. This review also summarizes the implications of the molten globule-type flexible structures to other Gram-positive bacterial toxins. Understanding these highly dynamic flexible structures in solution and their role in the function of bacterial toxins not only fills in the missing link of the high-resolution structures from X-ray crystallography but also provides vital information for better designing antidotes against those toxins.
- 23 October 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (11) , 2206
Open AccessClostridial Neurotoxins: Structure, Function and Implications to Other Bacterial Toxins
Gram-positive bacteria are ancient organisms. Many bacteria, including Gram-positive bacteria, produce toxins to manipulate the host, leading to various diseases. While the targets of Gram-positive bacterial toxins are diverse, many of those toxins use a similar mechanism to invade host cells and exert their functions. Clostridial neurotoxins produced by Clostridial tetani and Clostridial botulinum provide a classical example to illustrate the structure–function relationship of bacterial toxins. Here, we critically review the recent progress of the structure–function relationship of clostridial neurotoxins, including the diversity of the clostridial neurotoxins, the mode of actions, and the flexible structures required for the activation of toxins. The mechanism clostridial neurotoxins use for triggering their activity is shared with many other Gram-positive bacterial toxins, especially molten globule-type structures. This review also summarizes the implications of the molten globule-type flexible structures to other Gram-positive bacterial toxins. Understanding these highly dynamic flexible structures in solution and their role in the function of bacterial toxins not only fills in the missing link of the high-resolution structures from X-ray crystallography but also provides vital information for better designing antidotes against those toxins.
- Open Access
Evolutionary Features in the Structure and Function of Bacterial Toxins
Toxins can function both as a harmful and therapeutic molecule, depending on their concentrations. The diversity in their function allows us to ask some very pertinent questions related to their origin and roles: (a) What makes them such effective molecules? (b) Are there evolutionary features encoded within the structures of the toxins for their function? (c) Is structural hierarchy in the toxins important for maintaining their structure and function? (d) Do protein dynamics play a role in the function of toxins? and (e) Do the evolutionary connections to these unique features and functions provide the fundamental points in driving evolution? In light of the growing evidence in structural biology, it would be appropriate to suggest that protein dynamics and flexibility play a much bigger role in the function of the toxin than the structure itself. Discovery of IDPs (intrinsically disorder proteins), multifunctionality, and the concept of native aggregation are shaking the paradigm of the requirement of a fixed three-dimensional structure for the protein’s function. Growing evidence supporting the above concepts allow us to redesign the structure-function aspects of the protein molecules. An evolutionary model is necessary and needs to be developed to study these important aspects. The criteria for a well-defined model would be: (a) diversity in structure and function, (b) unique functionality, and (c) must belong to a family to define the evolutionary relationships. All these characteristics are largely fulfilled by bacterial toxins. Bacterial toxins are diverse and widely distributed in all three forms of life (Bacteria, Archaea and Eukaryotes). Some of the unique characteristics include structural folding, sequence and functional combination of domains, targeting a cellular process to execute their function, and most importantly their flexibility and dynamics. In this work, we summarize certain unique aspects of bacterial toxins, including role of structure in defining toxin function, uniqueness in their enzymatic function, and interaction with their substrates and other proteins. Finally, we have discussed the evolutionary aspects of toxins in detail, which will help us rethink the current evolutionary theories. A careful study, and appropriate interpretations, will provide answers to several questions related to the structure-function relationship of proteins, in general. Additionally, this will also allow us to refine the current evolution theories.
Open AccessEvolutionary Features in the Structure and Function of Bacterial Toxins
Toxins can function both as a harmful and therapeutic molecule, depending on their concentrations. The diversity in their function allows us to ask some very pertinent questions related to their origin and roles: (a) What makes them such effective molecules? (b) Are there evolutionary features encoded within the structures of the toxins for their function? (c) Is structural hierarchy in the toxins important for maintaining their structure and function? (d) Do protein dynamics play a role in the function of toxins? and (e) Do the evolutionary connections to these unique features and functions provide the fundamental points in driving evolution? In light of the growing evidence in structural biology, it would be appropriate to suggest that protein dynamics and flexibility play a much bigger role in the function of the toxin than the structure itself. Discovery of IDPs (intrinsically disorder proteins), multifunctionality, and the concept of native aggregation are shaking the paradigm of the requirement of a fixed three-dimensional structure for the protein’s function. Growing evidence supporting the above concepts allow us to redesign the structure-function aspects of the protein molecules. An evolutionary model is necessary and needs to be developed to study these important aspects. The criteria for a well-defined model would be: (a) diversity in structure and function, (b) unique functionality, and (c) must belong to a family to define the evolutionary relationships. All these characteristics are largely fulfilled by bacterial toxins. Bacterial toxins are diverse and widely distributed in all three forms of life (Bacteria, Archaea and Eukaryotes). Some of the unique characteristics include structural folding, sequence and functional combination of domains, targeting a cellular process to execute their function, and most importantly their flexibility and dynamics. In this work, we summarize certain unique aspects of bacterial toxins, including role of structure in defining toxin function, uniqueness in their enzymatic function, and interaction with their substrates and other proteins. Finally, we have discussed the evolutionary aspects of toxins in detail, which will help us rethink the current evolutionary theories. A careful study, and appropriate interpretations, will provide answers to several questions related to the structure-function relationship of proteins, in general. Additionally, this will also allow us to refine the current evolution theories.
- Open Access
- 31 August 2018
- Published by Portland Press Ltd. in Neuronal Signaling
- Vol. 2 (3) , NS20180058
Therapeutic use of botulinum toxin in pain treatment
Botulinum toxin is one of the most potent molecule known to mankind. A neurotoxin, with high affinity for cholinergic synapse, is effectively capable of inhibiting the release of acetylcholine. On the other hand, botulinum toxin is therapeutically used for several musculoskeletal disorders. Although most of the therapeutic effect of botulinum toxin is due to temporary skeletal muscle relaxation (mainly due to inhibition of the acetylcholine release), other effects on the nervous system are also investigated. One of the therapeutically investigated areas of the botulinum neurotoxin (BoNT) is the treatment of pain. At present, it is used for several chronic pain diseases, such as myofascial syndrome, headaches, arthritis, and neuropathic pain. Although the effect of botulinum toxin in pain is mainly due to its effect on cholinergic transmission in the somatic and autonomic nervous systems, research suggests that botulinum toxin can also provide benefits related to effects on cholinergic control of cholinergic nociceptive and antinociceptive systems. Furthermore, evidence suggests that botulinum toxin can also affect central nervous system (CNS). In summary, botulinum toxin holds great potential for pain treatments. It may be also useful for the pain treatments where other methods are ineffective with no side effect(s). Further studies will establish the exact analgesic mechanisms, efficacy, and complication of botulinum toxin in chronic pain disorders, and to some extent acute pain disorders.
- 31 August 2018
- Published by Portland Press Ltd. in Neuronal Signaling
- Vol. 2 (3) , NS20180058
Open AccessTherapeutic use of botulinum toxin in pain treatment
Botulinum toxin is one of the most potent molecule known to mankind. A neurotoxin, with high affinity for cholinergic synapse, is effectively capable of inhibiting the release of acetylcholine. On the other hand, botulinum toxin is therapeutically used for several musculoskeletal disorders. Although most of the therapeutic effect of botulinum toxin is due to temporary skeletal muscle relaxation (mainly due to inhibition of the acetylcholine release), other effects on the nervous system are also investigated. One of the therapeutically investigated areas of the botulinum neurotoxin (BoNT) is the treatment of pain. At present, it is used for several chronic pain diseases, such as myofascial syndrome, headaches, arthritis, and neuropathic pain. Although the effect of botulinum toxin in pain is mainly due to its effect on cholinergic transmission in the somatic and autonomic nervous systems, research suggests that botulinum toxin can also provide benefits related to effects on cholinergic control of cholinergic nociceptive and antinociceptive systems. Furthermore, evidence suggests that botulinum toxin can also affect central nervous system (CNS). In summary, botulinum toxin holds great potential for pain treatments. It may be also useful for the pain treatments where other methods are ineffective with no side effect(s). Further studies will establish the exact analgesic mechanisms, efficacy, and complication of botulinum toxin in chronic pain disorders, and to some extent acute pain disorders.
- 22 November 2016
- Published by Springer Nature
- p. 29-72
Relevance of Intrinsic Disorder in Protein Structure and Function
- 22 November 2016
- Published by Springer Nature
- p. 29-72
Relevance of Intrinsic Disorder in Protein Structure and Function
- 22 November 2016
- Published by Springer Nature
- p. 73-112
Implication of Molten Globule on the Function and Toxicity of a Protein
- 22 November 2016
- Published by Springer Nature
- p. 73-112
Implication of Molten Globule on the Function and Toxicity of a Protein
- 22 November 2016
- Published by Springer Nature
- p. 1-4
Introduction
- 22 November 2016
- Published by Springer Nature
- p. 5-28
Introduction to Protein Folding